Due to the unique capital needs of groundbreaking research, growing biotech companies often turn to the public market for financing. Thus, fair and efficient capital markets are vital to the success of biopharmaceutical innovation. Though the public capital markets are an essential component of the biotech financing ecosystem, roadblocks that decrease the capital potential of an offering, increase regulatory costs, reduce long-term liquidity and shareholder value, or distract a company from its core mission have the potential to deter or delay necessary offerings. These barriers reduce the viability of the public market as a capital formation option for emerging biotechs, ultimately harming issuers, investors, and patients alike.
![US Department of the Treasury Seal](png/msc_us-treasury-seala0e6.png)
The Treasury Department announced a pilot program involving the Foreign Investment Risk Review Modernization Act (FIRRMA), triggering reforms to the Committee on Foreign Investment in the U.S. (CFIUS), the interagency committee tasked with reviewing transactions with foreign investors that may pose national security risks.
![Join BIOAction](png/bioaction680e.png)
Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.
![Sanofi logo](jpg/sanofi_color_jpg_double%20helix.jpg)
![Eli Lilly and Company](png/eli%20lilly%20and%20company.png)
![Amgen logo](png/amgen_color_png_double%20helix.png)
![Genentech logo](png/genentech_color_png_double%20helix.png)
![Merck_logo_2022](png/merck_color_.png)
![Avantor](png/avantor-bio-dh-578.png)
![GSK logo](png/gsk_color_png.png)
![Pfizer Inc Logo](png/pfizer_logo_color_rgb%20(1).png)
![Johnson and Johnson](png/johnson-johnson-bio-dh-578.png)
![Takeda logo](jpg/takeda_color_jpg_premier.jpg)
![Travere logo](png/travere_color_png_helix%20large.png)